文献速递肝病消化道肿瘤与早癌

基于单发肿瘤>7 cm和多发肿瘤超出up-to-seven标准的早期与中期肝细胞癌改良分期

A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7 cm and multiple tumours beyond up-to-seven criteria.
PubMed 文献 · Aliment Pharmacol Ther · 2018-12-02

该研究利用两个中心986例肝切除患者作为训练队列、另一中心694例作为验证队列,评估肿瘤大小对总生存的预测价值并确定7 cm为最佳截断值。结果显示多发肿瘤超出米兰标准但符合up-to-seven标准者生存与符合米兰标准者相似,单发>7 cm者生存与BCLC-B期相似,据此提出BCLC-A和-B的改良分期,其C-index高于原版并在验证队列中得到支持。

要点

  • 多发肿瘤超出米兰标准但符合up-to-seven标准者总生存和无病生存与符合米兰标准者相似,归入改良BCLC-A期。
  • 肿瘤大小预测总生存的ROC曲线下面积为0.778,7 cm为识别单发肿瘤患者生存优于BCLC-B期的最佳截断值。
  • 单发>7 cm者总生存与BCLC-B期相似,归入改良BCLC-B期;改良分期C-index高于原版并在验证队列中得到支持。

核心结论

  • 基于单发肿瘤>7 cm和多发肿瘤超出up-to-seven标准的BCLC-A和-B改良分期可能更准确预测肝细胞癌患者预后。
  • 肝切除可能使可切除的超出米兰标准的多灶性肝细胞癌患者获益。

研究设计与样本

  • 训练队列为来自两个机构的986例接受肝切除的肝细胞癌患者,验证队列为来自另一机构的694例患者。
  • 采用时间依赖性ROC曲线分析评估肿瘤大小对总生存的预测性能并确定最佳截断值,采用Harrell一致性指数(C-index)评估区分能力。

主要发现

  • 多发肿瘤超出米兰标准但符合up-to-seven标准者的总生存和无病生存与多发肿瘤符合米兰标准者相似。
  • 肿瘤大小预测总生存的ROC曲线下面积为0.778,7 cm为识别单发肿瘤患者总生存高于BCLC-B期患者的最佳截断值。
  • 单发肝细胞癌>7 cm者的总生存与BCLC-B期患者相似。
  • 改良BCLC分类的总生存和无病生存C-index高于原版,验证队列支持上述发现。

关键数值与推荐

  • 多发肿瘤超出米兰标准但符合up-to-seven标准者归入改良BCLC-A期。
  • 单发肝细胞癌>7 cm者归入改良BCLC-B期。

临床怎么用

  • 作者认为基于单发肿瘤>7 cm和多发肿瘤超出up-to-seven标准的BCLC-A和-B改良分期可能更准确预测肝细胞癌患者预后。
  • 作者认为肝切除可能使可切除的超出米兰标准的多灶性肝细胞癌患者获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Barcelona Clinic Liver Cancer (BCLC) staging system is the most widely used staging system for hepatocellular carcinoma (HCC). However, the classifications of early (BCLC-A) and intermediate (BCLC-B) stage HCC remain controversial. AIM: To refine the staging of BCLC-A and -B. METHODS: A total of 986 patients with HCC undergoing liver resection from two institutions formed the training cohort, and 694 from another institution were the validation cohort. Time-dependent receiver operating characteristic (ROC) curve analysis was performed to evaluate the performance of tumour size in predicting overall survival (OS), and determined the optimised cut-off. Discriminatory performance was evaluated using Harrell's concordance index (C-index). RESULTS: Patients with multiple tumours exceeding Milan criteria but within up-to-seven criteria had similar OS and disease-free survival (DFS) to those with multiple tumours meeting Milan criteria, and were assigned to the modified BCLC-A stage. The area under the ROC curve of tumour size for predicting OS was 0.778, and the diameter of 7 cm was the optimal cut-off to identify patients with single tumours who had higher OS than BCLC-B stage patients. Due to the similar OS, patients with single HCCs >7 cm were assigned to the modified BCLC-B stage. The C-indexes of the modified BCLC classification for OS and DFS were higher compared to the original version. The findings were supported by the validation cohort. CONCLUSIONS: The modified staging of BCLC-A and -B, based on single tumour >7 cm and multiple tumours beyond up-to-seven criteria, could be more accurate to predict the prognosis of HCC patients. Liver resection could benefit patients with resectable multifocal HCCs beyond the Milan criteria.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wang YY, Zhong JH, Xu HF, et al. A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7 cm and multiple tumours beyond up-to-seven criteria. Aliment Pharmacol Ther. 2018. PMID: 30506713. doi:10.1111/apt.15074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。